Literature DB >> 9374868

Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes reduced with nicotinamide adenine dinucleotide phosphate and the very tight-binding inhibitor PT523.

V Cody1, N Galitsky, J R Luft, W Pangborn, A Rosowsky, R L Blakley.   

Abstract

Structural data for two independent crystal forms (monoclinic, C2, and orthorhombic, P2(1)2(1)2(1)) of the ternary complex of the potent antitumor agent PT523 [N alpha-(4-amino-4-deoxypteroyl)-N delta-hemiphthaloyl-L-ornithine], reduced nicotinamide adenine dinucleotide phosphate (NADPH), and recombinant human dihydrofolate reductase (hDHFR) reveals multiple binding orientations for the hemiphthaloyl group of the inhibitor. Analysis of these data shows that PT523 binds with its pteridine ring in the same orientation observed for methotrexate (MTX) analogues. However, in each structure, the hemiphthaloyl ring occupies three alternate conformations. In the C2 lattice, the phthaloyl moiety binds in two extended conformations, A and C, with each conformer having a 180 degrees flip of the o-carboxylate group, and a third, lower occupancy conformer B, with the phthaloyl group folded within contact of the active-site pocket. In the orthorhombic lattice, PT523 also has three conformers for the phthaloyl group; however, these differ from those observed in the monoclinic lattice. Two major conformers, A and C, are displaced on either side of the extended position observed in the C2 lattice, one near the folded B conformer of the C2 lattice and the other extended. These conformers form tighter intermolecular contacts than those in the C2 lattice. Conformer B is folded back away from the active site in a unique position. There are also significant differences in the conformation of the adenine-ribose moiety of NADPH in both complexes that differ from that observed for other inhibitor-NADPH-hDHFR ternary complexes. These data suggest that the added intermolecular contacts made by the hemiphaloyl group of PT523 contribute to its tighter binding to hDHFR than MTX, which does not extend as far from the active site and cannot make these contacts. These crystallographic observations of multiple conformations for the hemiphthaloyl group are in general agreement with solution NMR data for the binding of PT523 to hDHFR [Johnson et al. (1997) Biochemistry 36, 4399-4411], which show that the hemiphthaloyl group may adopt more than one conformation. However, the crystallographic data reveal more discretely occupied positions than can be interpreted from the solution data. These results suggest that crystal packing interactions may influence their stability.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9374868     DOI: 10.1021/bi971711l

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  15 in total

1.  A comparison of the pharmacophore identification programs: Catalyst, DISCO and GASP.

Authors:  Yogendra Patel; Valerie J Gillet; Gianpaolo Bravi; Andrew R Leach
Journal:  J Comput Aided Mol Des       Date:  2002 Aug-Sep       Impact factor: 3.686

2.  Linking High-Throughput Screens to Identify MoAs and Novel Inhibitors of Mycobacterium tuberculosis Dihydrofolate Reductase.

Authors:  John P Santa Maria; Yumi Park; Lihu Yang; Nicholas Murgolo; Michael D Altman; Paul Zuck; Greg Adam; Chad Chamberlin; Peter Saradjian; Peter Dandliker; Helena I M Boshoff; Clifton E Barry; Charles Garlisi; David B Olsen; Katherine Young; Meir Glick; Elliott Nickbarg; Peter S Kutchukian
Journal:  ACS Chem Biol       Date:  2017-08-29       Impact factor: 5.100

3.  2,4-Diamino-5-(2'-arylpropargyl)pyrimidine derivatives as new nonclassical antifolates for human dihydrofolate reductase inhibition.

Authors:  Oztekin Algul; Janet L Paulsen; Amy C Anderson
Journal:  J Mol Graph Model       Date:  2010-11-11       Impact factor: 2.518

Review 4.  Tetrazoles via Multicomponent Reactions.

Authors:  Constantinos G Neochoritis; Ting Zhao; Alexander Dömling
Journal:  Chem Rev       Date:  2019-02-01       Impact factor: 60.622

5.  In pursuit of virtual lead optimization: pruning ensembles of receptor structures for increased efficiency and accuracy during docking.

Authors:  Erin S D Bolstad; Amy C Anderson
Journal:  Proteins       Date:  2009-04

6.  In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery.

Authors:  Manoj Kumar; Rajakrishnan Vijayakrishnan; Gita Subba Rao
Journal:  Mol Divers       Date:  2009-08-21       Impact factor: 2.943

7.  In pursuit of virtual lead optimization: the role of the receptor structure and ensembles in accurate docking.

Authors:  Erin S D Bolstad; Amy C Anderson
Journal:  Proteins       Date:  2008-11-15

8.  The Z isomer of 2,4-diaminofuro[2,3-d]pyrimidine antifolate promotes unusual crystal packing in a human dihydrofolate reductase ternary complex.

Authors:  Vivian Cody; Jim Pace; Lu Lin; Aleem Gangjee
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-07-21

9.  Multiple conformers in active site of human dihydrofolate reductase F31R/Q35E double mutant suggest structural basis for methotrexate resistance.

Authors:  Jordan P Volpato; Brahm J Yachnin; Jonathan Blanchet; Vanessa Guerrero; Lucie Poulin; Elena Fossati; Albert M Berghuis; Joelle N Pelletier
Journal:  J Biol Chem       Date:  2009-05-28       Impact factor: 5.157

10.  Structural analysis of a holoenzyme complex of mouse dihydrofolate reductase with NADPH and a ternary complex with the potent and selective inhibitor 2,4-diamino-6-(2'-hydroxydibenz[b,f]azepin-5-yl)methylpteridine.

Authors:  Vivian Cody; Jim Pace; Andre Rosowsky
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2008-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.